Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 334

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 334
---
359 Conversion of convertible notes, net188— 6 — — 6 Stock-based compensation—— 15,813 — — 15,813 Net loss—— — (14,677)— (14,677)Other comprehensive income—— — — 115 115 Balance as of March 31, 202549,451,223$5 $892,367 $(658,858)$(258)$233,256 

 Common StockAdditionalPaid-InCapitalAccumulatedDeficit AccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’Equity  SharesAmountBalance as of December 31, 2023 46,723,143$5 $803,260 $(556,239)$1,644 $248,670 Issuance of common stock in connection with equity award plans337,963— 1,205 — — 1,205 Stock-based compensation—— 11,664 — — 11,664 Net loss—— — (25,279)— (25,279)Other comprehensive loss—— — — (1,657)(1,657)Balance as of March 31, 202447,061,106$5 $816,129 $(581,518)$(13)$234,603 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 Three Months Ended March 31, 20252024Operating activitiesNet loss$(14,677)$(25,279)Reconciliation of net loss to net cash (used in) provided by operating activities:Stock-based compensation15,803 11,450 Depreciation and amortization6,052 5,664 Inventory reserves and firm commitment losses2,349 237 Amortization of debt discount and offering costs433 414 Unrealized foreign exchange gain(658)(1,734)Non-cash lease expense390 237 Other(356)281 Change in operating assets and liabilities:Accounts receivable(16,833)12,969 Prepaid and other current assets(3,029)918 Inventory(2,672)(964)Other assets(92)11 Accounts payable, accrued expenses and other liabilities11,737 11,277